CD19 and cryohydrocytosis: In agreement with previously published data, there was a significant increase in the percentage of CD19+ B cells in pre-treatment JDM patients compared with age-matched CHC; a phenomenon that was normalized by 7–30 months on-treatment (Figure 1A).